-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Large Increase in Short Interest
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Large Increase in Short Interest
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,800,000 shares, an increase of 9.8% from the November 30th total of 1,640,000 shares. Approximately 6.2% of the shares of the company are sold short. Based on an average trading volume of 306,400 shares, the short-interest ratio is presently 5.9 days.
iTeos Therapeutics Price Performance
Shares of ITOS opened at $19.53 on Tuesday. iTeos Therapeutics has a 1-year low of $16.21 and a 1-year high of $52.43. The stock has a market cap of $694.78 million, a PE ratio of 2.84 and a beta of 1.38. The firm has a fifty day moving average price of $19.85 and a 200 day moving average price of $21.20.
Get iTeos Therapeutics alerts:iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). iTeos Therapeutics had a net margin of 57.48% and a return on equity of 42.62%. The company had revenue of $19.49 million during the quarter, compared to analysts' expectations of $42.05 million. As a group, equities analysts expect that iTeos Therapeutics will post 2.85 EPS for the current fiscal year.
Institutional Investors Weigh In On iTeos Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Prairiewood Capital LLC purchased a new stake in shares of iTeos Therapeutics in the third quarter valued at about $615,000. Alps Advisors Inc. purchased a new stake in shares of iTeos Therapeutics in the second quarter valued at about $434,000. Rafferty Asset Management LLC raised its holdings in shares of iTeos Therapeutics by 2.1% in the second quarter. Rafferty Asset Management LLC now owns 99,368 shares of the company's stock valued at $2,047,000 after buying an additional 2,067 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of iTeos Therapeutics by 22.7% in the second quarter. Principal Financial Group Inc. now owns 167,750 shares of the company's stock valued at $3,455,000 after buying an additional 31,004 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its holdings in shares of iTeos Therapeutics by 39.1% in the second quarter. Virtus ETF Advisers LLC now owns 5,790 shares of the company's stock valued at $119,000 after buying an additional 1,629 shares during the last quarter.iTeos Therapeutics Company Profile
(Get Rating)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Featured Articles
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- These 3 Tech Stocks Are in for a Happier New Year
- Can Duke Energy Stock Continue Powering Higher?
- Tyson Foods: Growth, Momentum, Growth At A Reasonable Price
- Ready for a Recession? Here's One Defensive Stock You Can't Miss
- Should You Store Your Capital in Pure Storage Stock?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ITeos治疗公司(纳斯达克代码:ITOS-GET评级)是12月份空头股数价格大幅增长的接受者。截至12月15日,空头股数共有180万股,比11月30日的164万股增加了9.8%。该公司约6.2%的股份被卖空。以平均成交量306,400股计算,目前短息比率为5.9天。
ITeos治疗药物的性价比
周二,伊藤忠商事的股价开盘报19.53美元。ITeos治疗公司的一年低点为16.21美元,一年高位为52.43美元。该股市值为6.9478亿美元,市盈率为2.84倍,贝塔系数为1.38。该公司的50日移动平均价为19.85美元,200日移动平均价为21.20美元。
到达ITeos治疗公司警报:ITOS治疗公司(纳斯达克代码:ITOS-GET评级)上一次公布季度收益是在11月10日星期四。该公司公布本季度每股收益为0.03美元,低于分析师普遍预期的0.07美元(0.04美元)。ITeos治疗公司的净利润率为57.48%,股本回报率为42.62%。该公司当季营收为1,949万美元,高于分析师预期的4,205万美元。股票分析师预计,iTeos治疗公司本财年的每股收益将达到2.85欧元。
机构投资者对iTeos治疗公司的看法
一些机构投资者和对冲基金最近买卖了该股的股票。Prairiewood Capital LLC在第三季度购买了iTeos治疗公司的新股份,价值约615,000美元。Alps Advisors Inc.在第二季度购买了iTeos治疗公司的新股,价值约43.4万美元。Rafferty Asset Management LLC在第二季度将其在iTeos Treeutics的股票持有量增加了2.1%。Rafferty Asset Management LLC现在拥有99,368股该公司的股票,价值2,047,000美元,在上个季度又购买了2,067股。信安金融集团在第二季度增持了iTeos Treateutics股票22.7%。在上个季度增持了31,004股后,信安金融集团目前持有167,750股该公司股票,价值3,455,000美元。最后,Virtus ETF Advisers LLC在第二季度将其在iTeos Treeutics的股票持有量增加了39.1%。Virtus ETF Advisers LLC现在拥有5790股该公司股票,价值11.9万美元,在上个季度又购买了1,629股。ITeos治疗公司简介
(获取评级)
ITeos治疗公司是一家临床阶段的生物制药公司,致力于为患者发现和开发免疫肿瘤疗法。该公司的产品线包括处于第二阶段临床试验的腺苷A2AR拮抗剂的小分子拮抗剂InupAdant,以及处于第1/2阶段临床试验的TIGIT或具有Ig和ITIM结构域的T细胞免疫受体拮抗剂EOS-448,以及用于激活树突状细胞和巨噬细胞并促进抗体依赖的细胞毒性或ADCC活性的Fc?R。
专题文章
- 免费获取StockNews.com关于iTeos治疗的研究报告(ITOS)
- 这三只科技股将迎来一个更快乐的新年
- 杜克能源类股能否继续走高?
- 泰森食品:增长、动力、合理价格的增长
- 准备好迎接经济衰退了吗?这里有一只你不能错过预期的防御性股票
- 您是否应该将您的资本存储在纯存储股票中?
接受iTeos治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对iTeos治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧